<DOC>
	<DOCNO>NCT00511069</DOCNO>
	<brief_summary>Ph+ leukemia ( i.e.Chronic Myelogenous Leukemia ( CML ) ( Ph+ ) Acute Lymphoblastic Leukemia malignant clonal disorder hemopoietic stem cell due reciprocal translocation genetic material chromosome 9 22 give rise translocation ( 9 ; 22 ) ( q2.2 ; q2.1 ) . The translocation cause formation new hybrid gene ( bcr-abl ) cod 185 kb 210 kb cytoplasmic protein ( P185 P210 respectively ) autophosphorylation activate number signal pathway involve cell proliferation , maturation , apoptosis adhesion , lead malignant cell transformation1-3 . The course disease go chronic phase ( CP ) , usually last year , characterize massive myeloid hyperplasia hyperleukocytosis splenomegaly . The CP almost always follow accelerate blastic phase ( ABP ) leukemic process acquire characteristic acute leukemia . The ABP usually last month terminates death patient3 . The frequency CML western country range 10 15 per million person ( age - standardize ) . It rare child . The median age 55 year . Current treatment CML include conventional chemotherapy , allogeneic bone marrow transplantation ( allo BMT ) , alpha-interferon ( alpha-IFN ) imatinib .</brief_summary>
	<brief_title>Velcade ( Bortezomib - PS341 ) Treatment Patients Over 18 Years With Ph+ Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Inclusion Criteria chronic phase patient : 1 . Age &gt; /=18 year 2 . Ph positive 3 . Absence CHR 3 month imatinib 4 . Loss previously obtain CHR imatinib alone 5 . Absence CCgR within 12 month imatinib alone 6 . Loss previously obtain CCgR imatinib alone 7 . Written inform consent Exclusion Criteria chronic phase patient : 1 . Age &lt; 18 2 . Performance status ( ECOG/WHO ) &gt; 2 ( see Appendix 2 ) 3 . Inability provide write informed consent 4 . Pregnancy 5 . Accelerated blastic phase 6 . Formal refusal recommendation safe contraception 7 . Alcohol drug addiction 8 . Altered hepatic renal function define AST/ALT bilirubin &gt; 3 time upper normal limit ( UNL ) 9 . Serum creatinine &gt; 265 umol/l &gt; 3.0 mg/dl 10 . Any disease condition advise responsible physician would make treatment dangerous patient would make patient ineligible study , include physical , psychiatric , social behavioural problem . Inclusion criterion accelerate blastic phase acute lymphoblastic leukemia Ph+ patient : 1 . Age &gt; /=18 year 2 . Ph positive 3 . Loss previous hematological response imatinib alone , progression ABP ( see section 14 definition ) 4 . Performance status ( ECOG/WHO ) 5 . Written inform consent Exclusion criterion accelerate blastic phase acute lymphoblastic leukemia Ph+ patient : 1 . Age &lt; 18 2 . Performance status ( ECOG/WHO ) &gt; 2 ( see Appendix 2 ) 3 . Inability provide write informed consent 4 . Pregnancy 5 . Chronic Phase disease 6 . Formal refusal recommendation safe contraception 7 . Alcohol drug addiction 8 . Altered hepatic renal function define AST/ALT bilirubin &gt; 3 time upper normal limit ( UNL ) 9 . Serum creatinine &gt; 265 umol/l &gt; 3.0 mg/dl 10 . Any disease condition advise responsible physician would make treatment dangerous patient would make patient ineligible study , include physical , psychiatric , social behavioural problem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Bortezomib</keyword>
	<keyword>CML033</keyword>
</DOC>